Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is a cholinesterase inhibitor presented as an oral dosage form for oral use. It is employed to improve neuromuscular transmission in patients with myasthenia gravis and to aid recovery of bowel function after surgery.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide through regulated distribution channels, ensuring product integrity, compliance with EU standards, and timely delivery to end‑users.

Mestinon acts as a cholinesterase inhibitor and is used in disorders where acetylcholine deficiency impairs neuromuscular function. - Myasthenia gravis: improves skeletal muscle strength and reduces fatigue. - Postoperative ileus: accelerates return of intestinal motility after abdominal surgery. - Myasthenic crisis: supports respiratory muscle function as an adjunctive therapy.

Pyridostigmine bromide may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea - Diarrhea - Increased salivation - Sweating Serious or Rare Side Effects: - Cholinergic crisis (muscle weakness, respiratory failure) - Severe bronchospasm - Cardiac arrhythmias (bradycardia, AV block) - Anaphylactic reactions

When prescribing pyridostigmine bromide, several safety considerations should be observed. - Renal impairment: adjust dose based on renal function. - History of asthma or COPD: monitor for bronchospasm. - Concomitant anticholinergic drugs: may reduce therapeutic effect. - Signs of cholinergic excess: watch for muscle twitching or cramps. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at room temperature: keep in original packaging, protect from moisture.

Pyridostigmine bromide can interact with other medicines, altering its efficacy or safety. Major Interactions (Avoid): - Other cholinesterase inhibitors (e.g., neostigmine): additive cholinergic effects. - Succinylcholine: prolonged neuromuscular blockade. - Aminoglycoside antibiotics (e.g., gentamicin): may diminish neuromuscular transmission. Moderate Interactions (Monitor Closely): - Beta‑adrenergic blockers: may enhance bradycardia. - Anticholinergic agents (e.g., atropine): may counteract drug action.